National Actos Bladder Cancer Attorneys File Wrongful Death Lawsuit on Behalf of the Estate of a Kentucky Man who developed Bladder Cancer and Died

Share Article

Parker Waichman LLP has filed a lawsuit alleging that Takeda’s diabetes drug Actos caused bladder cancer and subsequent death in a Kentucky man.

Parker Waichman LLP

Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed a lawsuit on behalf of the estate of a Kentucky man who developed bladder cancer and subsequently died, allegedly due to the use of Actos. The suit was filed on June 15th in the U.S. District Court for the Western District of Louisiana (Case No. 6:12-cv-01710) where it is currently pending in the multidistrict litigation as part of In Re: Actos (Pioglitazone) Products Liability Litigation (MDL No. 6:11-md-2299). The lawsuit names Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North America, Inc., Takeda Pharmaceutical Company Limited and Eli Lilly and Co. as Defendants. (

According to the complaint, the Plaintiff-Decedent took Actos as prescribed between 2010 and 2011. As an alleged result of taking the drug, he developed bladder cancer and died last November. The suit alleges that use of Actos caused severe mental and physical pain and suffering leading up to the Plaintiff-Decedent’s death, economic loss due to medical expenses and living related expenses as a result of a new lifestyle. The lawsuit further alleges that the Defendant knew or should have known that Actos is associated with bladder cancer, but failed to adequately warn the public. The suit claims that the Plaintiff-Decedent would not have taken Actos if he was fully aware of the risks.

Actos was approved in 1999 to treat patients with type 2 diabetes. According to the lawsuit, it is one of Takeda’s top-sellers and accounts for approximately 27 percent of the company’s revenue; in 2008, Actos was the tenth best-selling drug in the US.

The U.S. Food and Drug Administration (FDA) publicly acknowledged the potential link between Actos and bladder cancer in a Safety Communication issued September 2010. After reviewing the interim results of an ongoing ten-year study by Kaiser Permanente, the agency noted a statistically significant increased risk of bladder cancer after two years of Actos exposure. The FDA released an updated Safety Communication last June, this time stating that the risk was significant after taking the medication for more than one year; apparently, the risk increased with time and dosage. According to the Safety Communication, patients taking Actos for more than one year were 40 percent more likely to develop bladder cancer compared to those who had never taken the drug. The agency addressed the risk by updating the Warnings and Precautions section of Actos’ label. (;    

Concerns over the link between Actos and bladder cancer have certainly not been limited to the United States. Last June, only days before the FDA made its announcements, use of the drug was halted in France and Germany after data from the French Medicines Agency revealed an increased risk in male patients after one year of exposure, the lawsuit stated. In April, Canada’s healthcare regulatory agency updated Actos warning label to include the risk of bladder cancer. (

Most recently, a study in the British Medical Journal found that patients exposed to Actos for at least two years were twice as likely to develop bladder cancer. (

Parker Waichman LLP continues to offer free legal consultations to victims of Actos. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting the firm's Actos injury page at Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).

For more information regarding Actos side effect lawsuits and Parker Waichman LLP, please visit or call 1-800-LAW-INFO (1-800-529-4636).

Parker Waichman LLP
Gary Falkowitz, Managing Attorney
(800) LAW-INFO
(800) 529-4636

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Gary Falkowitz, Managing Attorney
Parker Waichman LLP
(800) 529-4636
Email >
Visit website